The Preemptive Analgesic Efficacy of Nefopam

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: Nefopam

Criteria

Inclusion Criteria:

• Patients diagnosed with breast cancer

• Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy

• American Society of Anesthesiologists physical status I or II

Exclusion Criteria:

• Refusal

• Seizure

• Cardiac disease

• Monoamine oxidase inhibitor user

• Urologic disease

• Glucoma

• Preoperative analgesic drug medication

• Pregnancy

• Recurred breast cancer patient